A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

• ClinicalTrials.gov Identifier: NCT05070247
• Recruitment Status: Recruiting
• First Posted: October 7, 2021
• Last Update Posted: March 8, 2024
• Sponsor: Takeda
• Information provided by (Responsible Party): Takeda

Study Description

Brief Summary:

This study is about TAK-500, given either alone or with pembrolizumab, in adults with select locally advanced or metastatic solid tumors.

The aims of the study are:

• to assess the safety profile of TAK-500 when given alone and when given with pembrolizumab.
• to assess the anti-tumor effects of TAK-500, when given alone and when given with pembrolizumab, in adults with locally advanced or metastatic solid tumors.

Participants may receive TAK-500 for up to 1 year. Participants may continue with their treatment if they have continuing benefit and if this is approved by their study doctor. Participants who are receiving TAK-500 either alone or with pembrolizumab will continue with their treatment until their disease progresses or until they or their study doctor decide they should stop this treatment.

Condition or disease	Intervention/treatment	Phase
Pancreatic Cancer; Hepatocellular Cancer; Mesothelioma; Breast Cancer; Gastric Cancer; Esophageal Cancer; Nasopharyngeal Cancer; Kidney Cancer; Squamous Cell Cancer of Head and Neck (SCCHN); Non-small Cell Lung Cancer (NSCLC), Non-squamous	Drug: TAK-500; Drug: Pembrolizumab	Phase 1; Phase 2

Detailed Description:

The drug being tested in this study is called TAK-500. The study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of TAK-500 when used as a single agent (SA) and in combination with pembrolizumab in participants with locally advanced or metastatic solid tumors.

The study will be conducted in 2 phases: Dose Escalation and Dose Expansion Phase. The study will enroll approximately 313 participants (approximately 82 in the Dose Escalation Phase and approximately 231 in Dose Expansion Phase). The dose escalation phase will determine the recommended dose of TAK-500 along with the combination agents for the dose expansion phase. All the participants will be assigned to one of the 9 arms:

• Dose Escalation: TAK-500 Single Agent (SA)
• Dose Escalation: TAK-500 + Pembrolizumab
• Dose Expansion: 2L NSCLC: TAK-500 recommended dose 1 for expansion (RDE 1) + Pembrolizumab
• Dose Expansion: 2L NSCLC: TAK-500 recommended dose 2 for expansion (RDE 2) + Pembrolizumab
• Dose Expansion: 3L NSCLC: TAK-500 (RDE 1) SA
• Dose Expansion: 3L NSCLC: TAK-500 (RDE 2) SA
• Dose Expansion: 2L Pancreatic Adenocarcinoma: TAK-500 (RDE 1) + Pembrolizumab
• Dose Expansion: 2L Pancreatic Adeno: TAK-500 (RDE 1) SA
• Dose Expansion: 3L RCC: TAK-500 (RDE 1) + Pembrolizumab

This multi-center trial will be conducted globally. Participants with demonstrated clinical benefit may continue treatment beyond 1 year if approved by the sponsor.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 313 participants
• Allocation: Non-Randomized
• Intervention Model: Sequential Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: An Open-label, Dose Escalation and Expansion, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of TAK-500, a Novel Stimulator of Interferon Genes Agonist, as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Select Locally Advanced or Metastatic Solid Tumors
• Actual Study Start Date: April 14, 2022
• Estimated Primary Completion Date: August 11, 2026
• Estimated Study Completion Date: August 11, 2026

Arms and Interventions

Arm	Intervention/treatment
Experimental: Dose Escalation: TAK-500 Single Agent (SA); TAK-500 dose escalation starting at 8 microgram per kilogram (mcg/kg), infusion, intravenously, once on Day 1 of each 21-day treatment cycle (once every 3 weeks, Q3W) or once on Day 1, 15 and 29 of each 42-day treatment cycle (once every 2 weeks, Q2W), for up to 1 year.	Drug: TAK-500; TAK-500 intravenous infusion.
Experimental: Dose Escalation: TAK-500 + Pembrolizumab; TAK-500, infusion, intravenously, once on Day 1 of each 21-day treatment cycle (once every 3 weeks, Q3W) or once on Day 1, 15 and 29 of each 42-day treatment cycle (once every 2 weeks, Q2W), for up to 1 year, along with pembrolizumab 200 milligram (mg) infusion, intravenously, once on Day 1 of each 21-day treatment cycle or on Days 1 and 22 in a 42-day cycle (Q3W) for up to 1 year. The exact starting dose of TAK-500 will be determined from the results of the TAK-500 SA arm dose escalation.	Drug: TAK-500; TAK-500 intravenous infusion.; Drug: Pembrolizumab; Pembrolizumab intravenous infusion.
Experimental: Dose Expansion: 2L NSCLC: TAK-500 + Pembrolizumab (RDE 1); Participants with second-line (2L) non-small cell lung cancer (NSCLC) will receive TAK-500, infusion, intravenously, in a 42-day treatment cycle (Q2W or Q3W) with pembrolizumab 200 mg infusion, intravenously, in a 42-day treatment cycle (Q3W) for up to 1 year. The recommended dose (RDE 1) and schedule of TAK-500 for expansion will be based on the results of the TAK-500 in combination with pembrolizumab Dose Escalation arm.	Drug: TAK-500; TAK-500 intravenous infusion.; Drug: Pembrolizumab; Pembrolizumab intravenous infusion.
Experimental: Dose Expansion: 2L NSCLC: TAK-500 + Pembrolizumab (RDE 2); Participants with 2L NSCLC will receive TAK-500, infusion, intravenously, in a 42-day treatment cycle (Q2W or Q3W) with pembrolizumab 200 mg infusion, intravenously, in a 42-day treatment cycle (Q3W) for up to 1 year. The recommended dose (RDE 2) and schedule of TAK-500 for expansion will be based on the results of the TAK-500 in combination with pembrolizumab Dose Escalation arm.	Drug: TAK-500; TAK-500 intravenous infusion.; Drug: Pembrolizumab; Pembrolizumab intravenous infusion.
Experimental: Dose Expansion: 3L NSCLC: TAK-500 (RDE 1) SA; Participants with third-line (3L) NSCLC will receive TAK-500, infusion, intravenously, in a 42-day treatment cycle (Q2W or Q3W) for up to 1 year. The recommended dose (RDE 1) and schedule of TAK-500 for expansion will be based on the results of the TAK-500 as single agent in Dose Escalation arm.	Drug: TAK-500; TAK-500 intravenous infusion.
Experimental: Dose Expansion: 3L NSCLC: TAK-500 (RDE 2) SA; Participants with 3L NSCLC will receive TAK-500, infusion, intravenously, in a 42-day treatment cycle (Q2W or Q3W) for up to 1 year. The recommended dose (RDE 2) and schedule of TAK-500 for expansion will be based on the results of the TAK-500 as single agent in Dose Escalation arm.	Drug: TAK-500; TAK-500 intravenous infusion.
Experimental: Dose Expansion: 2L Pancreatic Adenocarcinoma: TAK-500 + Pembrolizumab (RDE 1); Participants with 2L Pancreatic Adenocarcinoma will receive TAK-500, infusion, intravenously, in a 42-day treatment cycle (Q2W or Q3W) with pembrolizumab 200 mg infusion, intravenously, in a 42-day treatment cycle (Q3W) for up to 1 year. The recommended dose (RDE 1) and schedule of TAK-500 for expansion will be based on the results of the TAK-500 in combination with pembrolizumab Dose Escalation arm.	Drug: TAK-500; TAK-500 intravenous infusion.; Drug: Pembrolizumab; Pembrolizumab intravenous infusion.
Experimental: Dose Expansion: 2L Pancreatic Adeno: TAK-500 (RDE 1) SA; Participants with 2L Pancreatic Adenocarcinoma will receive TAK-500, infusion, intravenously, in a 42-day treatment cycle (Q2W or Q3W) for up to 1 year. The recommended dose (RDE 1) and schedule of TAK-500 for expansion will be based on the results of the TAK-500 as single agent in Dose Escalation arm.	Drug: TAK-500; TAK-500 intravenous infusion.
Experimental: Dose Expansion: 3L RCC: TAK-500 + Pembrolizumab (RDE 1); Participants with 3L renal clear cell carcinoma (RCC) will receive TAK-500, infusion, intravenously, in a 42-day treatment cycle (Q2W or Q3W) with pembrolizumab 200 mg infusion, intravenously, in a 42-day treatment cycle (Q3W) for up to 1 year. The recommended dose (RDE 1) and schedule of TAK-500 for expansion will be based on the results of the TAK-500 in combination with pembrolizumab Dose Escalation arm.	Drug: TAK-500; TAK-500 intravenous infusion.; Drug: Pembrolizumab; Pembrolizumab intravenous infusion.

Outcome Measures

Primary Outcome Measures :

1. Dose Escalation: Number of Participants With Grade 3 or Higher TEAEs [ Time Frame: Up to approximately 50 months ]
   TEAE Grades will be evaluated as per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0.
2. Dose Escalation: Number of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs) [ Time Frame: Up to approximately 50 months ]
3. Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLTs) [ Time Frame: Up to approximately 50 months ]
   DLT will be defined as any of the TEAEs that occur during Cycle 1 and are considered by the investigator to be at least possibly related to TAK-500 as a SA or in combination with pembrolizumab. Toxicity will be evaluated according to NCI CTCAE version 5.0.
4. Dose Escalation: Number of Participants Reporting one or More Serious Adverse Event (SAEs) [ Time Frame: Up to approximately 50 months ]
5. Dose Escalation: Number of Participants With one or More TEAEs Leading to Dose Modifications and Treatment Discontinuations [ Time Frame: Up to approximately 50 months ]
6. Dose Expansion: Overall Response Rate (ORR) [ Time Frame: Up to approximately 50 months ]
   ORR is defined as the percentage of participants who achieve confirmed partial response (cPR) or confirmed complete response (cCR) (determined by the investigator) during the study in the response-evaluable population. ORR will be assessed as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. Complete response (CR): defined as disappearance of all target and non- target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than <10 mm. Partial response (PR): defined as at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters. cPR or cCR is defined as a PR or CR that is confirmed with additional imaging 6 weeks after initial response.

Secondary Outcome Measures :

1. Dose Escalation and Dose Expansion: Cmax: Maximum Serum Concentration for TAK-500 [ Time Frame: Cycle 1 Day 1, Cycle 2 Day 1, Cycle 3 Day 1 and Cycle 4 Day 1: pre-infusion and at multiple time points (up to 21 days) post-infusion (Cycle length=21 days) ]
2. Dose Escalation and Dose Expansion: Tmax: Time to Reach the Maximum Serum Concentration (Cmax) for TAK-500 [ Time Frame: Cycle 1 Day 1, Cycle 2 Day 1, Cycle 3 Day 1 and Cycle 4 Day 1: pre-infusion and at multiple time points (up to 21 days) post-infusion (Cycle length=21 days) ]
3. Dose Escalation and Dose Expansion: AUCt: Area Under the Serum Concentration-time Curve From Time 0 to Time t for TAK-500 [ Time Frame: Cycle 1 Day 1, and Cycle 2 Day 1: pre-infusion and at multiple time points (up to 21 days) post-infusion (Cycle length=21 days) ]
4. Dose Escalation and Dose Expansion: AUCinf: Area Under the Serum Concentration-time Curve From Time 0 to Infinity for TAK-500 [ Time Frame: Cycle 1 Day 1, and Cycle 2 Day 1: pre-infusion and at multiple time points (up to 21 days) post-infusion (Cycle length=21 days) ]
5. Dose Escalation and Dose Expansion: t1/2: Terminal Disposition Phase Half-life for TAK-500 [ Time Frame: Cycle 1 Day 1, and Cycle 2 Day 1: pre-infusion and at multiple time points (up to 21 days) post-infusion (Cycle length=21 days) ]
6. Dose Escalation and Dose Expansion: CL: Total Clearance After Intravenous Administration for TAK-500 [ Time Frame: Cycle 1 Day 1, and Cycle 2 Day 1: pre-infusion and at multiple time points (up to 21 days) post-infusion (Cycle length=21 days) ]
7. Dose Escalation and Dose Expansion: Vss: Volume of Distribution at Steady State After Intravenous Administration for TAK-500 [ Time Frame: Cycle 1 Day 1, and Cycle 2 Day 1: pre-infusion and at multiple time points (up to 21 days) post-infusion (Cycle length=21 days) ]
8. Dose Escalation and Dose Expansion: Changes in Intratumoral Tumor Cell Infiltration [ Time Frame: Up to 23 days after first administration of TAK-500 ]
   Measurement of changes in tumor immune cell infiltration will be measured by immunohistochemistry or in-situ hybridization on fresh tumor biopsies taken pre and post treatment (up to 23 days after first administration of TAK-500) for each participant.
9. Dose Escalation and Dose Expansion: Number of Participants With Positive Anti-drug Antibody (ADA) and Acquired Immunogenicity [ Time Frame: Up to approximately 50 months ]
10. Dose Escalation: Overall Response Rate (ORR) [ Time Frame: Up to approximately 50 months ]
    ORR is defined as the percentage of participants who achieve cPR or cCR (determined by the investigator) during the study in the response-evaluable population. ORR will be assessed as per RECIST Version 1.1. CR: defined as disappearance of all target and non- target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than <10 mm. PR: defined as at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters. cPR or cCR is defined as a PR or CR that is confirmed with additional imaging 6 weeks after initial response.
11. Dose Escalation and Dose Expansion: Disease Control Rate (DCR) [ Time Frame: Up to approximately 50 months ]
    DCR is defined as the percentage of participants who achieve cCR + cPR + stable disease (SD) or better (determined by the investigator) greater than (>) 6 weeks during the study in the response-evaluable population. DCR will be assessed as per RECIST Version 1.1. CR: disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR: at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD). PD: at least a 20% increase in the sum of diameters of target lesions.
12. Dose Escalation and Dose Expansion: Duration of Response (DOR) [ Time Frame: Up to approximately 50 months ]
    DOR is defined as the time from the date of first documentation of a cPR or better to the date of first documentation of PD for responders (cPR or better). Responders without documentation of PD will be censored at the date of last response assessment that is SD or better. DOR will be assessed as per RECIST Version 1.1. PR: at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD). PD: at least a 20% increase in the sum of diameters of target lesions.
13. Dose Escalation and Dose Expansion: Time to Response (TTR) [ Time Frame: Up to approximately 50 months ]
    TTR is defined as the time from the date of first dose administration to the date of first documented cPR or better (determined by the investigator) in the safety population. TTR will be assessed as per RECIST Version 1.1. PR: at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters.
14. Dose Expansion: Progression Free Survival (PFS) [ Time Frame: Up to approximately 50 months ]
    PFS is defined as the time from date of study treatment to the first documented PD based on RECIST v.1.1, or death due to any cause, whichever occurs first. PD: at least a 20% increase in the sum of diameters of target lesions.
15. Dose Expansion: Overall Survival (OS) [ Time Frame: Up to approximately 50 months ]
    OS is defined as the time from the date of first dose administration to the date of death.
16. Dose Expansion: Number of Participants With Grade 3 or Higher TEAEs [ Time Frame: Up to approximately 50 months ]
    TEAE Grades will be evaluated as per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0.
17. Dose Expansion: Number of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs) [ Time Frame: Up to approximately 50 months ]
18. Dose Expansion: Number of Participants With Dose Limiting Toxicities (DLTs) [ Time Frame: Up to approximately 50 months ]
    DLT will be defined as any of the TEAEs that occur during Cycle 1 and are considered by the investigator to be at least possibly related to TAK-500 as a SA or in combination with pembrolizumab. Toxicity will be evaluated according to NCI CTCAE version 5.0.
19. Dose Expansion: Number of Participants Reporting one or More Serious Adverse Event (SAEs) [ Time Frame: Up to approximately 50 months ]
20. Dose Expansion: Number of Participants With one or More TEAEs Leading to Dose Modifications and Treatment Discontinuations [ Time Frame: Up to approximately 50 months ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1. 2. Individuals with the following pathologically confirmed (cytological diagnosis is adequate) select locally advanced or metastatic solid tumors, whose disease has progressed on or are intolerant to standard therapy:

1. Gastroesophageal (esophageal, gastroesophageal junction, and gastric) adenocarcinoma, pancreatic adenocarcinoma, hepatocellular carcinoma (HCC), nonsquamous non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), mesothelioma, triple-negative breast cancer (TNBC), renal clear cell carcinoma (RCC) and nasopharyngeal carcinoma (NPC). Participants who are intolerant to all standard therapies are those who have developed clinical or laboratory abnormalities that prevent continued drug administration as evaluated by the principal investigator at the time of screening.

2. For dose expansion in 2L nonsquamous NSCLC (TAK-500 plus pembrolizumab):

   • Participants with pathologically confirmed (cytological diagnosis is adequate) locally advanced or metastatic nonsquamous NSCLC.
   • Participants may not have a known targetable driver mutation, rearrangement or amplification (eg, EGFR, ALK, MET, ROS1, BRAF, KRASG12C, etc.).

   • Must have had disease progression while on or following 1 prior line of therapy:

     1. Disease progression while on or following at least 6 weeks of 1 prior anti-PD-(L)1 therapy in the recurrent locally advanced or metastatic setting.

   OR Disease progression/recurrence within 6 months of the completion of anti-PD-(L)1 therapy if administered in the adjuvant/neoadjuvant setting.

   Prior anti-PD-(L)1 therapy may have been given with or without an anti-CTLA4 antibody and/or chemotherapy (eg, carboplatin and pemetrexed).

   • Participants are eligible regardless of PD-L1 status.

3. For dose expansion in 3L nonsquamous NSCLC (TAK-500 SA):

   • Participants with pathologically confirmed (cytological diagnosis is adequate) locally advanced or metastatic nonsquamous NSCLC.
   • Participants may not have a known targetable driver mutation, rearrangement or amplification (eg, EGFR, ALK, MET, ROS1, BRAF, KRASG12C, etc.).

   • Must have had disease progression while on or following 2 prior lines of therapy:

     1. Disease progression while on or following at least 6 weeks of 1 prior anti-PD-(L)1 therapy in the recurrent locally advanced or metastatic setting OR Disease progression/recurrence within 6 months of the completion of 1 prior anti-PD-(L)1 therapy if administered in the adjuvant/neoadjuvant setting.

        Prior anti-PD-(L)1 therapy may have been given with or without an anti-CTLA4 antibody and/or chemotherapy (eg, carboplatin and pemetrexed).

     2. Participants must have had disease progression while on or after 1 or 2 lines of chemotherapy in the recurrent locally advanced or metastatic setting. If the anti-PD-(L)1 therapy is given in combination with chemotherapy, participant must have progressed on an additional line of chemotherapy.
   • Participants are eligible regardless of PD-L1 status.

4. For dose expansion in 2L pancreatic adenocarcinoma (TAK-500 SA and TAK-500 plus pembrolizumab):

   • Participants with pathologically confirmed (cytological diagnosis is adequate) locally advanced or metastatic pancreatic adenocarcinoma.

   • Must have had disease progression while on or following 1 prior line of therapy:

   1. One prior line of fluorouracil- or gemcitabine-based chemotherapy (eg, FOLFIRINOX, FOLFOX, FOLFIRI, gemcitabine/nab-paclitaxel) in the metastatic/recurrent locally advanced setting.

   Prior chemotherapy in the neoadjuvant/adjuvant setting does not qualify unless the participant had progression of disease within 6 months of completion of neoadjuvant/adjuvant chemotherapy.

   • Must not have had prior exposure to anti-PD-(L)1 therapy.

   • Participants with MSI-H/dMMR disease are not eligible.

   • Participants are eligible regardless of PD-L1 status.

5. For dose expansion in 3L RCC (TAK-500 plus pembrolizumab):

   • Participants with pathologically confirmed (cytological diagnosis is adequate) locally advanced or metastatic RCC.

   • Must have had disease progression while on or following 2 prior lines of therapy:

     1. Disease progression while on or following at least 6 weeks of 1 prior anti-PD-(L)1 therapy in the recurrent locally advanced or metastatic setting.

        OR Disease progression/recurrence within 6 months of the completion of anti-PD-(L)1 therapy if administered in the adjuvant/neoadjuvant setting.

        Prior anti-PD-(L)1 therapy may have been given with or without an anti-CTLA4 antibody and/or an anti-VEGFR TKI.

     2. Participants must have had prior therapy with 1 or 2 lines of VEGFR TKIs in the metastatic/recurrent locally advanced setting. If anti-PD-(L)1 therapy was given in combination with a VEGFR TKI, the participant must have had progressive disease on an additional line of therapy (eg, VEGFR TKI or VEGFR TKI-containing combination).

   • Participants are eligible regardless of PD-L1 status. 3. Must have at least 1 RECIST version 1.1 measurable lesion. Lesions in previously irradiated areas (or other local therapy) should not be selected as measurable/target lesions unless there has been demonstrated radiographic progression in that lesion. RECIST v1.1 target lesions must include at least 1 lesion that was not previously irradiated.

     4. Adequate bone marrow, renal, and hepatic functions, as determined by the following laboratory parameters:

   • Absolute neutrophil count (ANC) greater than or equal to (>=) 1000/microliter (mcL), platelet count >=75,000/mcL, and hemoglobin >= 8.0 grams per deciliter (g/dL) without growth factor support for ANC or transfusion support for platelets within 14 days before the first study treatment dose.
   • Total bilirubin <=1.5 times the institutional upper limit of normal (ULN). For participants with Gilbert's disease or HCC, <=3 milligrams per deciliter (mg/dL).
   • Serum alanine aminotransferase and aspartate aminotransferase <=3.0*ULN or <=5.0*ULN with liver metastases or HCC.
   • Albumin >=3.0 g/dL.

   • Calculated creatinine clearance using the Cockcroft-Gault formula >=30 mL/minute.

     5 . Left ventricular ejection fraction (LVEF) >50%, as measured by echocardiogram or multiple gated acquisition scan (MUGA) within 4 weeks before receiving the first dose of study drug.

     6. For participants with HCC only: Child-Pugh score less than or equal to 7 (Child-Pugh A or B7).

     7. Clinically significant toxic effects of previous therapy have recovered to Grade 1 (per National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] Version 5.0) or baseline, except for alopecia, Grade 2 peripheral neuropathy, and/or autoimmune endocrinopathies with stable endocrine replacement therapy.

     8. Participants previously treated with fully human/humanized antineoplastic monoclonal antibodies must not have received treatment with such antibodies for at least 4 weeks or the time period equal to the dosing interval, whichever is shorter. No washout period is required for prior treatment with pembrolizumab or other anti-programmed cell death protein 1 (PD-1) antibodies, although the first study dose of these drugs must not occur at an interval less than standard of care (that is, 3 weeks for 200 mg of IV pembrolizumab).

Exclusion Criteria:

1. History of any of the following <=6 months before first dose of study drug(s): congestive heart failure New York Heart Association Grade III or IV, unstable angina, myocardial infarction, persistent hypertension >=160/100 millimeters of mercury (mmHg) despite optimal medical therapy, ongoing cardiac arrhythmias of Grade >2 (including atrial flutter/fibrillation or intermittent ventricular tachycardia), other ongoing serious cardiac conditions (example, Grade 3 pericardial effusion or Grade 3 restrictive cardiomyopathy), or symptomatic cerebrovascular events. Chronic, stable atrial fibrillation on stable anticoagulation therapy, including low molecular-weight heparin, is allowed.
2. QT interval with Fridericia correction method >450 milliseconds (men) or >475 milliseconds (women) on a 12- lead ECG during the screening period.
3. Grade >=2 hypotension (that is, hypotension for which nonurgent intervention is required) at screening or during C1D1 predose assessment.
4. Oxygen saturation <92% on room air at screening or during C1D1 predose assessment.
5. Treatment with other STING agonists/antagonists, Toll-like receptor agonists or CCR2 agonist/antagonist within the past 6 months.
6. Active diagnosis of pneumonitis, interstitial lung disease, severe chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, other restrictive lung diseases, acute pulmonary embolism, or Grade >=2 pleural effusion not controlled by tap or requiring indwelling catheters.
7. Grade >=2 fever of malignant origin.
8. Chronic, active hepatitis (example, participants with known hepatitis B surface antigen seropositive and/or detectable hepatitis C virus [HCV] RNA).
9. History of hepatic encephalopathy.
10. Prior or current clinically significant ascites, as measured by physical examination, that requires active paracentesis for control.
11. Treatment with any investigational products or other anticancer therapy (including chemotherapy, targeted agents, and immunotherapy), within 14 days or 5 half-lives, whichever is shorter, before C1D1 of study drug(s).
12. Radiation therapy within 14 days (42 days for radiation to the lungs) and/or systemic treatment with radionuclides within 42 days before C1D1 of study drug(s). Participants with clinically relevant ongoing pulmonary complications from prior radiation therapy are not eligible.

13. Use of systemic corticosteroids or other immunosuppressive therapy, concurrently or within 14 days of C1D1 of study drug(s), with the following exceptions:

    • Topical, intranasal, inhaled, ocular, intra-articular, and/or other nonsystemic corticosteroids.
    • Physiological doses of replacement steroid therapy (example, for adrenal insufficiency), not to exceed the equivalent of 10 mg prednisone daily.
14. Recipients of allogeneic or autologous stem cell transplantation or organ transplantation.

Additional criteria specific for participants in TAK-500 and pembrolizumab combination arm only:

1. Contraindication to the administration of a pembrolizumab or prior intolerance to pembrolizumab or other anti-PD-1 or anti-programmed cell death protein ligand 1 antibody.
2. History of intolerance to any component of the study treatment agents or known serious or severe hypersensitivity reaction to any of the study drugs or their excipients. (Pembrolizumab is formulated with L-histidine, polysorbate 80, and sucrose.

Contacts and Locations

Contacts

Contact: Takeda Contact; +1-877-825-3327; medinfoUS@takeda.com

Locations

United States, Alabama

Univeristy of Alabama at Birmingham; Recruiting

Birmingham, Alabama, United States, 35294

Contact: Site Contact 919-525-0054 aakashdesai@uabmc.edu

Principal Investigator: Aakash Desai

United States, California

City of Hope Comprehensive Cancer Center; Recruiting

Duarte, California, United States, 91010

Contact: Site Contact 626-256-9200 vchung@coh.org

Principal Investigator: Vincent Chung

University of California San Diego; Recruiting

La Jolla, California, United States, 92093

Contact: Site Contact 858-822-5354 spatel@ucsd.edu

Principal Investigator: Sandep Patel

United States, Colorado

University of Colorado - Anschutz Medical Campus - PPDS; Recruiting

Aurora, Colorado, United States, 80045

Contact: Site Contact 303-724-5499 jennifer.diamond@ucdenver.edu

Principal Investigator: Jennifer Diamond

Sarah Cannon Research Institute; Recruiting

Denver, Colorado, United States, 80218

Contact: Site Contact 720-754-4653 jason.henry2@sarahcannon.com

Principal Investigator: Jason Henry

United States, Florida

Sylvester Comprehensive Cancer Center; Not yet recruiting

Miami, Florida, United States, 33136

Contact: Site Contact 305-396-8889 estelarodriguez@miami.edu

Principal Investigator: Estela Rodriguez

United States, Illinois

Northwestern; Not yet recruiting

Chicago, Illinois, United States, 60611

Contact: Site Contact 312-695-6180 jd-patel@northwestern.edu

Principal Investigator: Jyoti Patel

United States, Massachusetts

Dana Farber Cancer Institute; Recruiting

Boston, Massachusetts, United States, 02215

Contact: Site Contact 617-632-3000 harshabad_singh@dfci.harvard.edu

Principal Investigator: Harshabad Singh

United States, New York

New York University; Not yet recruiting

New York, New York, United States, 10016-4744

Contact: Site Contact 212-731-5445 minas.economides@nyulangone.org

Principal Investigator: Minas Economides

United States, Pennsylvania

Fox Chase Cancer Center; Recruiting

Philadelphia, Pennsylvania, United States, 19111

Contact: Site Contact 215-214-1676 anthony.olszanski@fccc.edu

Principal Investigator: Anthony Olszanski

United States, Tennessee

Sarah Cannon Cancer Institute; Not yet recruiting

Nashville, Tennessee, United States, 37203

Contact: Site Contact 615-329-7274 meredith.pelster@sarahcannon.com

Principal Investigator: Meredith Pelster

United States, Texas

START South Texas Accelerated Research Therapeutics; Recruiting

San Antonio, Texas, United States, 78229

Contact: Site Contact 210-593-5265 drew.rasco@startsa.com

Principal Investigator: Drew Rasco

Sponsors and Collaborators

Takeda

Investigators

• Study Director: Study Director; Takeda

More Information

Additional Information:

To obtain more information on the study, click here/on this link 

• Responsible Party: Takeda
• ClinicalTrials.gov Identifier: NCT05070247
• Other Study ID Numbers: TAK-500-1001; 2023-505374-15 ( Other Identifier: EU CT Number )
• First Posted: October 7, 2021
• Last Update Posted: March 8, 2024
• Last Verified: March 2024

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Yes
• Plan Description: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
• Supporting Materials: Study Protocol; Statistical Analysis Plan (SAP); Informed Consent Form (ICF); Clinical Study Report (CSR)
• Access Criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
• URL: https://vivli.org/ourmember/takeda/

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No

Keywords provided by Takeda:

Drug Therapy

Additional relevant MeSH terms:

Mesothelioma; Neoplasms, Squamous Cell; Carcinoma, Squamous Cell; Nasopharyngeal Neoplasms; Nasopharyngeal Carcinoma; Liver Neoplasms; Carcinoma, Hepatocellular; Head and Neck Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Adenoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms, Mesothelial; Adenocarcinoma; Carcinoma; Pharyngeal Neoplasms; Otorhinolaryngologic Neoplasms; Nasopharyngeal Diseases; Pharyngeal Diseases; Stomatognathic Diseases; Otorhinolaryngologic Diseases; Liver Diseases; Pembrolizumab; Antineoplastic Agents, Immunological; Antineoplastic Agents; Immune Checkpoint Inhibitors; Molecular Mechanisms of Pharmacological Action